Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE by Landewé, Robert et al.
ORIGINAL RESEARCH
Induction of Sustained Clinical Remission in Early
Axial Spondyloarthritis Following Certolizumab Pegol
Treatment: 48-Week Outcomes from C-OPTIMISE
Robert Landewe´ . De´sire´e van der Heijde . Maxime Dougados .
Xenofon Baraliakos . Filip Van den Bosch . Karl Gaffney .
Lars Bauer . Bengt Hoepken . Natasha de Peyrecave . Karen Thomas .
Lianne S. Gensler
Received: April 17, 2020 / Published online: June 11, 2020
 The Author(s) 2020
ABSTRACT
Introduction: Achievement of remission is a
key treatment goal for patients with axial
spondyloarthritis (axSpA). C-OPTIMISE assessed
achievement of sustained clinical remission in
patients with axSpA, including radiographic
(r) and non-radiographic (nr) axSpA, during
certolizumab pegol (CZP) treatment, and sub-
sequent maintenance of remission following
CZP dose continuation, dose reduction or
withdrawal. Here, we report outcomes from the
first 48 weeks (induction period) of C-OPTI-
MISE, during which patients received open-la-
bel CZP.
Methods: C-OPTIMISE (NCT02505542) was a
two-part, multicenter, phase 3b study in adult
patients with early axSpA (r-/nr-axSpA),
including a 48-week open-label induction per-
iod followed by a 48-week maintenance period.
Patients with active adult-onset
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axSpA,\5 years’ symptom duration, and ful-
filling Assessment of SpondyloArthritis inter-
national Society classification criteria, were
included. During the induction period, patients
received a loading dose of CZP 400 mg at weeks
0, 2, and 4, followed by CZP 200 mg every
2 weeks (Q2W) up to week 48. The main out-
come of the 48-week induction period was the
achievement of sustained clinical remission
(defined as an Ankylosing Spondylitis Disease
Activity Score [ASDAS]\1.3 at week 32 and
\2.1 at week 36 [or vice versa], and\1.3 at
week 48).
Results: In total, 736 patients (407 with
r-axSpA, 329 with nr-axSpA) were enrolled into
the study. At week 48, 43.9% (323/736) of
patients achieved sustained remission, includ-
ing 42.8% (174/407) of patients with r-axSpA
and 45.3% (149/329) with nr-axSpA. Patients
also demonstrated substantial improvements in
axSpA symptoms, MRI outcomes and quality of
life measures. Adverse events occurred in 67.9%
(500/736) of patients, of which 6.0% (44/736)
were serious.
Conclusions: Over 40% of patients with early
axSpA achieved sustained remission during
48 weeks of open-label CZP treatment. Addi-
tionally, patients across the axSpA spectrum
demonstrated substantial improvements in
imaging outcomes and quality of life following
treatment. No new safety signals were
identified.
Trial Registration: NCT02505542.
Keywords: Axial spondyloarthritis; Clinical
remission; Early disease; TNF inhibitor
Key Summary Points
Why carry out this study?
Achievement of remission is a key
treatment goal for patients with axial
spondyloarthritis (axSpA), a chronic
inflammatory disease characterized by
chronic lower back pain and stiffness with
a subsequent loss of function that imposes
a substantial burden on patients’ quality
of life.
The induction period of C-OPTIMISE
assessed achievement of sustained clinical
remission in patients with early active
axSpA, including radiographic and non-
radiographic axSpA, during open-label
treatment with the TNF inhibitor
certolizumab pegol (CZP).
What was learned from the study?
After 48 weeks of CZP treatment, 43.9%
(323/736) of patients achieved sustained
remission, including 42.8% (174/407) of
patients with radiographic axSpA and
45.3% (149/329) with non-radiographic
axSpA. There were also substantial
improvements in axSpA signs and
symptoms, physical function, quality of
life, and MRI outcomes.
These results confirm that CZP is a
suitable treatment option for patients
across the broad axSpA spectrum, and
provide further support for the concept of
axSpA as a single disease, encompassing
both radiographic and non-radiographic
axSpA.
INTRODUCTION
Axial spondyloarthritis (axSpA) is a chronic
inflammatory disease that affects the axial
skeleton and is characterized by chronic lower
back pain. Peripheral manifestations include
arthritis, enthesitis, and dactylitis, while extra-
musculoskeletal manifestations of the disease
extend to acute anterior uveitis, psoriasis, and
inflammatory bowel disease, amongst others
[1, 2]. The two sub-types of axSpA, radiographic
axSpA (r-axSpA; also known as ankylosing
spondylitis) and non-radiographic axSpA (nr-
axSpA), are differentiated by the degree of
structural damage of the sacroiliac joints
observed using pelvic radiography (as part of
the modified New York classification criteria)
[2–4]. Despite this difference, the burden of
disease for patients in terms of clinical presen-
tation, quality of life, and extra-musculoskeletal
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manifestations is comparable between r-axSpA
and nr-axSpA [5, 6].
Symptom onset in axSpA often occurs in the
second to fourth decade of a patient’s life,
necessitating early and effective treatment to
limit the impact of the disease on physical
function, work and social productivity, and
overall quality of life [7]. In addition to this,
diagnosis is typically delayed for several years
after the onset of symptoms, although the
extent of this delay shows geographic variation
[8–12]. Efforts to reduce the diagnostic delay
have had limited success, with recent studies
still reporting delays of up to 14 years in some
regions [10, 12].
Current treatment options for patients with
axSpA include non-steroidal anti-inflammatory
drugs (NSAIDs) in combination with physical
exercise and physical therapy as a first-line
treatment, followed by tumor necrosis factor
inhibitors (TNFi) and interleukin (IL)-17A inhi-
bitors as second-line treatments [13]. Clinical
remission is now recommended as a major
treatment target in the Assessment of Spondy-
loArthritis international Society (ASAS)/Euro-
pean League Against Rheumatism (EULAR)
recommendations for axSpA and treat-to-target
recommendations for spondyloarthritis [14].
Once remission has been achieved, strategies for
the maintenance of remission are necessary to
prevent future deterioration in disease status.
Given the high cost of TNFi and patients
wanting to limit their long-term exposure to
biologic therapy, dose reduction and treatment
withdrawal of TNFi have been explored as
options for maintaining remission [15–17].
However, results from previous studies suggest
that complete treatment withdrawal in axSpA
often leads to relapse [18, 19]. In addition, there
are few controlled studies evaluating the main-
tenance of remission following dose reduction
and/or withdrawal, and none that evaluate this
in both the r- and nr-axSpA subpopulations.
The PEGylated, Fc-free TNFi certolizumab
pegol (CZP) is an effective and well-tolerated
treatment for patients with axSpA, and is
approved for the treatment of both r-axSpA and
nr-axSpA [14, 20, 21]. The phase 3b C-OPTIMISE
trial investigated the use of CZP for the induc-
tion and maintenance of remission in patients
with early axSpA, including those with r-axSpA
and nr-axSpA. Here we report outcomes from
the first 48 weeks of C-OPTIMISE, during which
patients were treated with open-label CZP to
induce sustained remission. Results from the
maintenance period of C-OPTIMISE are repor-
ted elsewhere [22].
METHODS
Study Design
C-OPTIMISE (ClinicalTrials.gov number
NCT02505542) was a two-part, multicenter
phase 3b study in adult patients with axSpA
(including r-axSpA and nr-axSpA) comprising a
48-week open-label induction period, followed
by a 48-week maintenance period [22]. The
study aimed to evaluate the induction of sus-
tained remission and the effect of CZP mainte-
nance dose continuation, reduction, or
withdrawal on flares in patients who had
achieved sustained remission (Fig. 1a).
During the induction period (baseline to
week 48), patients received a loading dose of
CZP 400 mg at weeks 0, 2 and 4, followed by
open-label CZP 200 mg every 2 weeks (Q2W)
until week 48. Patients achieving sustained
remission during this 48-week induction period
were eligible to proceed to the maintenance
phase of the C-OPTIMISE study. Sustained
remission was recorded as achieved when a
subject had an Ankylosing Spondylitis Disease
Activity Score (ASDAS) [23, 24]\ 1.3 at week 32
or 36 (if ASDAS was\ 1.3 at week 32, it must
have been\ 2.1 at week 36, or vice versa) and at
week 48.
The maintenance period (weeks 48–96) was a
randomized, double-blind period which inves-
tigated the efficacy and safety of CZP treatment
in patients who had achieved sustained remis-
sion during the induction period. These
patients were randomized to CZP 200 mg Q2W
(full maintenance dose), CZP 200 mg Q4W (re-
duced maintenance dose) or placebo (with-
drawal) [22].
The C-OPTIMISE study was approved by
institutional review boards and independent
ethics committees at participating sites
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Fig. 1 C-OPTIMISE study design (a) and patient
disposition (b). aThe LD consisted of CZP 400 mg at
weeks 0, 2 and 4. LD loading dose, r-axSpA radiographic
axial spondyloarthritis, nr-axSpA non-radiographic axial
spondyloarthritis, CZP certolizumab pegol, Q2W every
2 weeks, Q4W every 4 weeks, AE adverse event, LoE lack
of efficacy, LtF-u lost to follow-up
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(Supplementary Material) and was conducted in
accordance with local regulations and the
International Conference on Harmonization
Good Clinical Practice requirements, based on
the Declaration of Helsinki. All patients pro-
vided informed consent to participate.
Patients
Eligible patients were between the ages of 18
and 45 years, and had a documented diagnosis
of adult-onset axSpA which met ASAS classifi-
cation criteria [25], a symptom duration
of C 3 months but\ 5 years, and active disease
(defined as ASDAS C 2.1, Bath Ankylosing
Spondylitis Disease Activity Index [BASDAI]
C 4, and spinal pain C 4 on a 0–10 numerical
rating scale [BASDAI item 2]). In addition, all
patients must have had inadequate response,
contraindication, or intolerance to C 2 NSAIDs.
Both subpopulations of axSpA (r-axSpA and
nr-axSpA) were included in the study. Central
reading by two independent readers (plus
adjudicator, if necessary) was applied to all
radiographs. Patients fulfilling the ASAS classi-
fication criteria and the imaging criterion of the
modified New York classification criteria [26]
were classified as having r-axSpA. Those fulfill-
ing the ASAS classification criteria but not the
modified New York classification criteria, and
with objective signs of inflammation (C-reactive
protein level above the upper limit of normal
[10 mg/l], and/or evidence of active sacroiliitis
on magnetic resonance imaging) were classified
as having nr-axSpA.
Study Procedures
Patients visited their respective study sites for
administration of study drug and study assess-
ments at weeks 0, 2, 4, 12, 24, 32, 36, and week
48, plus an additional visit 3–5 days prior to the
week 48 visit. Patients were taught to self-ad-
minister their study medication at weeks 2 and
4, and then self-administered at each of the
remaining time points.
Outcomes
The primary outcome of C-OPTIMISE was the
proportion of patients not experiencing a flare
(ASDAS C 2.1 [high disease activity] at two
consecutive visits or ASDAS[3.5 [very high
disease activity] at any visit) during the main-
tenance period (weeks 48–96). These outcomes
are reported elsewhere [22].
The main secondary outcome (reported
herein) was the percentage of patients achieving
sustained remission at week 48, the end of the
open-label induction phase. Additional sec-
ondary outcomes included assessment of ASDAS
status (ASDAS inactive disease [ID], low disease
[LD] activity, high disease activity and very high
disease activity) [18] and change from baseline
in ASDAS major improvement (MI; ASDAS
reduction from baseline of C 2) and clinically
important improvement (CII; ASDAS reduction
from baseline of C 1.1) [18].
Other outcomes included change from
baseline in ASAS response rates (ASAS20,
ASAS40 and ASAS5/6), ASAS partial remission
(PR) [19, 20], BASDAI50, mean ASDAS, BASDAI
[21], Bath Ankylosing Spondylitis Functional
Index (BASFI) [22] and Bath Ankylosing
Spondylitis Metrology Index (BASMI; linear
definition) [23, 24], Ankylosing Spondylitis
Quality of Life (ASQoL) and 36-Item Short Form
Survey (SF-36) [27, 28], and MRI outcomes,
including sacroiliac joint Spondyloarthritis
Research Consortium of Canada (SIJ SPARCC)
score [29] and the Berlin modification of the
Ankylosing Spondylitis spine MRI score for
activity (ASspiMRI-a) [22]. Mean Maastricht
Ankylosing Spondylitis Enthesitis Score
(MASES) and tender and swollen joint counts
(44 joints evaluation) were also evaluated at
week 48.
Safety Data
Safety analyses included all patients who
received C 1 dose of study medication during
the induction period. Treatment-emergent
adverse events (TEAEs) are reported as the
number of patients experiencing each event
and were classified according to the Medical
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Dictionary for Regulatory Activities (MedDRA)
version 19.0. Serious TEAEs were defined as
medical occurrences that were life-threatening
or led to death, hospitalization, congenital
anomalies or birth defects, persistent or signifi-
cant disability, or were considered medically
important by the study investigator (regardless
of severity). Event rates (ER) per 100 patient-
years (PY) were calculated for all TEAEs and
serious TEAEs (to include repeat events in the
same patients).
Statistical Analysis
It was assumed that approximately 28% of
patients would achieve sustained remission at
the end of the open-label induction period.
Hence, 750 patients were planned for enrol-
ment into the study in order to provide suffi-
cient power to detect differences (at a two-sided
significance level of 0.05) between the CZP
200 mg Q2W and CZP 200 Q4W treatment
groups vs. placebo during the 48-week mainte-
nance period of the study.
The percentage of patients achieving sus-
tained remission is summarized using descrip-
tive statistics (counts and percentages).
Continuous data are summarized using mean
and standard deviation (SD). Missing data for
secondary outcomes were imputed using non-
responder imputation (NRI) for binary response
measures, and last observation carried forward
(LOCF) for continuous measures. For additional
outcomes (not primary or secondary), observed
data are reported.
Statistical analyses were performed using SAS
Version 9.3.
RESULTS
Patient Disposition and Baseline
Characteristics
Out of 1253 screened patients, 736 were enrol-
led in the open-label induction period, includ-
ing 407 patients with r-axSpA and 329 patients
with nr-axSpA (Fig. 1b). The majority of screen
failures (n = 461) were due to patients not
meeting study eligibility criteria. Baseline char-
acteristics were generally comparable for
patients with r-axSpA and nr-axSpA (Table 1).
However, as expected, a higher proportion of
patients with r-axSpA were male (78.4%) com-
pared to nr-axSpA (59.3%). Patients with
r-axSpA also had a longer average symptom
duration at baseline than those with nr-axSpA
(3.7 vs. 2.9 years).
Overall, 89.5% (659/736) axSpA patients
completed the open-label induction period,
including 89.2% (363/407) patients with
r-axSpA and 90.0% (296/329) patients with nr-
axSpA.
Of the 77 patients who discontinued during
the induction period after starting open-label
treatment, reasons for discontinuation included
adverse events, lack of efficacy, protocol viola-
tion, lost to follow-up, consent withdrawal and
‘other’ (Fig. 1b).
Achievement of Sustained Remission
After 48 weeks of open-label CZP treatment,
43.9% (323/736) patients had achieved sus-
tained remission according to the study defini-
tion (Fig. 2a), including 42.8% (174/407)
r-axSpA and 45.3% (149/329) nr-axSpA patients.
Over the 48-week open-label treatment period,
there was a gradual increase in the percentage of
patients who achieved and then maintained
ASDAS-ID (used in the definition of sustained
remission) up to week 48, with over a third
(35.6%) achieving and maintaining sustained
remission from week 12 onwards, and approxi-
mately half (52.0%) from week 24 onwards
(Fig. 2b).
Clinical and Quality of Life Outcomes
Clinical improvements were observed as early as
week 2 in the overall axSpA population, with
37.1% of patients reaching ASDAS\2.1 (in-
cluding 25.9 and 11.2% with ASDAS-LD and
ASDAS-ID, respectively; Fig. 3a). By week 4, half
of all patients (50.2%) had ASDAS\ 2.1.
At week 48, 75.2% of all patients had
ASDAS\2.1 (22.8% with ASDAS-LD and 52.5%
with ASDAS-ID), with comparable responses
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Table 1 Baseline demographics and disease characteristics for patients enrolled in the C-OPTIMISE study
All axSpA (n = 736) r-axSpA (n = 407) nr-axSpA (n = 329)
Age, years
Mean (SD) 32.9 (7.0) 33.7 (6.8) 32.1 (7.1)
Median (range) 33.0 (18–45) 34.0 (18–45) 32.0 (18–45)
Male, n (%) 514 (69.8) 319 (78.4) 195 (59.3)
BMI, kg/m2, mean (SD) 25.7 (4.9) 25.6 (4.7) 25.8 (5.1)
Race, n (%)
Caucasian 681 (92.5) 375 (92.1) 306 (93.0)
Asian 38 (5.2) 27 (6.6) 11 (3.3)
Other/mixed/missing 17 (2.3) 5 (1.2) 12 (3.6)
Geographic region, n (%)
North America 33 (4.5) 13 (3.2) 20 (6.1)
Western Europe 91 (12.4) 30 (7.4) 61 (18.5)
Eastern Europe 537 (73.0) 320 (78.6) 217 (66.0)
Asia 75 (10.2) 44 (10.8) 31 (9.4)
mNY positive, n (%) 407 (55.3) 407 (100.0) 0
Symptom duration, years
Mean (SD) 3.3 (2.2) 3.7 (2.5) 2.9 (1.7)
Median 3.5 4.0 2.9
Time since diagnosis, years
Mean (SD) 2.2 (1.7) 2.5 (1.8) 1.8 (1.6)
Median 1.6 2.3 1.1
HLA-B27 positive, n (%) 617 (83.8) 363 (89.2) 254 (77.2)
CRP[ULN, n (%) 344 (46.7) 210 (51.6) 134 (40.7)
Prior TNFi therapy, n (%) 32 (4.3) 20 (4.9) 12 (3.6)
History of enthesitis (heel), n (%) 184 (25.0) 102 (25.1) 82 (24.9)
MASES[ 0, n (%) 447 (60.7) 241 (59.2) 206 (62.6)
Peripheral arthritis,a n (%) 4 (0.5) 2 (0.5) 2 (0.6)
History of EMMs, n (%)
Uveitis 111 (15.1) 63 (15.5) 48 (14.6)
Inflammatory bowel disease 17 (2.3) 9 (2.2) 8 (2.4)
Psoriasis 45 (6.1) 24 (5.9) 21 (6.4)
Disease characteristics, mean (SD)
ASDAS 3.7 (0.8) 3.9 (0.8) 3.6 (0.8)
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amongst r-axSpA and nr-axSpA patients (74.2
and 76.5%, respectively; Table 2). This is com-
pared to just 1.5% who had ASDAS\2.1 at
study baseline. The percentage of patients
reaching ASAS PR at week 48 (57.3%) was sim-
ilar to the percentage achieving ASDAS-ID
(52.5%). Similar trends were observed in
ASAS20 and ASAS40 response rates, with 73.1
and 56.4% of patients achieving an ASAS20 and
ASAS40 response, respectively, by week 12, and
79.6 and 72.0% by week 48 (Fig. 3b).
Other outcome measures also demonstrated
improvements at week 48, including those
assessing disease activity (ASDAS and BASDAI),
physical function (BASFI), mobility (BASMI)
and quality of life (SF-36, ASQoL). All responses
were comparable between r-axSpA and nr-
axSpA subpopulations (Table 2).
cFig. 2 a Proportion of patients achieving sustained
remission following 48 weeks’ open-label CZP. b Kinetics
of ASDAS-ID and ASDAS\ 2.1 achievement to week 48
in the 323 patients who achieved sustained remission.
Non-responder imputation. ASDAS-ID Ankylosing
Spondylitis Disease Activity Score inactive disease, axSpA
axial spondyloarthritis, r-axSpA radiographic axial spondy-
loarthritis, nr-axSpA non-radiographic spondyloarthritis
Table 1 continued
All axSpA (n = 736) r-axSpA (n = 407) nr-axSpA (n = 329)
BASDAI 6.7 (1.4) 6.7 (1.4) 6.7 (1.4)
BASFI 5.3 (2.1) 5.4 (2.0) 5.2 (2.1)
BASMI 3.1 (1.5) 3.5 (1.6) 2.6 (1.3)
Tender joint count 2.6 (5.0) 1.9 (3.8) 3.4 (6.0)
Swollen joint countb 0.7 (2.1) 0.5 (1.4) 1.1 (2.7)
MASES, mean (SD) 2.5 (3.0) 2.3 (2.8) 2.7 (3.1)
Imaging (MRI), mean (SD)
SIJ SPARCC 8.0 (11.4) 8.2 (11.8) 7.9 (10.9)
ASspiMRI-a 3.1 (5.2) 4.6 (6.1) 1.4 (2.9)
Concomitant medication,c n (%)
NSAIDs 618 (84.0) 352 (86.5) 266 (80.9)
DMARDs 166 (22.6) 97 (23.8) 69 (21.0)
Induction period baseline characteristics are reported
ASDAS Ankylosing Spondylitis Disease Activity Score, ASspiMRI-a Ankylosing Spondylitis spine MRI score for activity,
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index,
BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, CRP C-reactive protein, CZP certolizumab
pegol, DMARD disease-modifying anti-rheumatic drug, EMM extra-musculoskeletal manifestation, HLA-B27 human
leukocyte antigen B27, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, mNY modified New York, MRI
magnetic resonance imaging, NSAID non-steroidal anti-inflammatory drug, Q2W every 2 weeks, Q4W every 4 weeks, SD
standard deviation, SIJ SPARCC sacroiliac joint Spondyloarthritis Research Consortium of Canada, TNF tumor necrosis
factor, ULN upper limit of normal
a Reported as previous history or ongoing at baseline
b 44 joints
c Any intake during induction period (weeks 0–48).
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MRI Outcomes
Improvements were also reported for MRI out-
comes assessing active inflammation in the SIJ
and spine at week 48 across both axSpA sub-
populations (Table 2). At baseline, mean SIJ
SPARCC scores were comparable in patients
with r-axSpA and nr-axSpA (8.2 and 7.9,
respectively), and demonstrated similar reduc-
tions over the 48 weeks to 1.4 and 1.5, respec-
tively. ASspiMRI-a scores were higher at baseline
in patients with r-axSpA compared to nr-axSpA
(4.6 and 1.4, respectively), but following
48 weeks’ treatment had reduced substantially
in both groups to 1.2 and 0.5, respectively.
Peripheral and Extra-Musculoskeletal
Manifestations
Despite higher baseline tender and swollen
joint counts in patients with nr-axSpA (3.4 and
1.1, respectively) compared with r-axSpA (1.9
and 0.5, respectively), at week 48 mean scores
had improved in both subpopulations (Table 2).
Improvements in enthesitis (MASES) were also
reported at week 48 across all subpopulations
(Table 2). In patients who had enthesitis at
baseline, by week 48, 72.6% (291/401) of all
patients had achieved full enthesitis resolution
(including 75.1% [160/213] r-axSpA patients
and 69.7% [131/188] nr-axSpA patients).
At baseline, 15.1% (111/736) patients had a
history of anterior acute uveitis (11 patients had
uveitis at screening). During the 48-week
induction period, 7.2% (8/111) of these patients
experienced a total of ten uveitis flares. In the
total population, including patients without
any history of uveitis, 1.4% (10/736) patients
experienced 13 uveitis flares.
At baseline, 17 of 736 (2.3%) patients had a
history of inflammatory bowel disease (nine
with r-axSpA and eight with nr-axSpA). Of these
17 patients, 3 (17.6%) had an exacerbation of
their inflammatory bowel disease during the
treatment period, all of whom had nr-axSpA.
There were four de novo cases of inflammatory
bowel disease, all in patients with r-axSpA.
Safety
During the 48-week open-label induction per-
iod, TEAEs were reported for 67.9% of axSpA
patients (67.3% of patients with r-axSpA and
68.7% of patients with nr-axSpA; Table 3).
Serious TEAEs were reported for 6.0% of axSpA
patients (ER = 6.74/100 PY). The rates of serious
TEAEs were similar for patients with r-axSpA
(6.1%, ER = 7.02/100 PY) and nr-axSpA patients
(5.8%, ER = 6.40/100 PY).
There were two reported cases of oppor-
tunistic infection, both serious and in patients
with r-axSpA; this included one case of pul-
monary tuberculosis (resolving at the time of
preliminary drop-out) and one of tuberculous
pleurisy (resolved). Patients were tested for the
signs and symptoms of latent or active TB
infection before CZP treatment; both of these
cases had an onset after the start of treatment,
were considered to be treatment-related, and
occurred in patients based in Romania. There
were 13 reported cases of oral herpes, and ten of
these were in patients with r-axSpA (2.5% of
r-axSpA patients); five of the 13 cases were
considered to be related to the study drug. A
single case of demyelinating disorder (optic
neuritis) was reported in a patient with nr-
axSpA and judged to be related to the study
drug by the investigator. There were no reported
cases of oral candidiasis, malignancy, serious
cardiovascular or bleeding events. No deaths
were reported.
DISCUSSION
The induction period of the C-OPTIMISE trial
evaluated the achievement of sustained
bFig. 3 a ASDAS disease states and b ASAS responses
during the 48-week induction period for the overall axSpA
population (N = 736). ASDAS disease states: last obser-
vation carried forward; ASAS response: non-responder
imputation, ASDAS-ID/LD/HD/vHD Ankylosing
Spondylitis Disease Activity Score inactive disease/low
disease/high disease/very high disease, ASAS Assessment of
Spondyloarthritis international Society, axSpA axial
spondyloarthritis
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remission in patients with early axSpA, includ-
ing both r- and nr-axSpA, during 48 weeks’
open-label CZP treatment. The definition of
remission in C-OPTIMISE was based on
achievement of ASDAS-ID (\1.3), a disease
activity measure in axSpA that is considered in
the ASAS/EULAR recommendations to reflect a
state of clinical remission [30, 31]. The defini-
tion of ‘sustained’ remission also corresponds to
that used in the ABILITY-3 study, by requiring
Table 3 Safety outcomes for r-axSpA and nr-axSpA subpopulations at the end of the induction period (week 48)
n (%), unless otherwise specified All axSpA (n = 736) r-axSpA (n = 407) nr-axSpA (n = 329)
CZP exposure duration (days)
Mean (SD) 317.1 (64.0) 315.4 (66.6) 319.3 (60.7)
Median (range) 336.0 (14–384) 336.0 (14–384) 336.0 (14–369)
Patient-years at risk 697.1 384.4 312.7
Any TEAE 500 (67.9) 274 (67.3) 226 (68.7)
Event rate per 100 PY 225.0 211.0 242.1
Serious TEAEs 44 (6.0) 25 (6.1) 19 (5.8)
Event rate per 100 PY 6.7 7.0 6.4
Discontinuation due to TEAEs 31 (4.2) 18 (4.4) 13 (4.0)
Drug-related TEAEs 194 (26.4) 105 (25.8) 89 (27.1)
TEAEs of interest
Opportunistic infections 2 (0.3) 2 (0.5) 0
Pulmonary tuberculosis 1 (0.1) 1 (0.2) 0
Tuberculous pleurisy 1 (0.1) 1 (0.2) 0
Oral candidiasis 0 0 0
Malignant or unspecified tumors 0 0 0
Serious cardiovascular events 0 0 0
Serious hematopoietic cytopenia 0 0 0
Serious bleeding events 0 0 0
Hepatic events 46 (6.3) 26 (6.4) 20 (6.1)
Liver function analyses 32 (4.3) 19 (4.7) 13 (4.0)
Hypersensitivity and anaphylactic reactions 3 (0.4) 0 3 (0.9)
Demyelinating disordersa 1 (0.1) 0 1 (0.3)
Deaths 0 0 0
axSpA axial spondyloarthritis, CZP certolizumab pegol, PY patient-years, Q2W every 2 weeks, Q4W every 4 weeks, TEAE
treatment-emergent adverse event
a The singular case of demyelinating disorder was optic neuritis, judged to be related to the study drug by the investigator.
Safety events are reported for the safety set (N = 736) according to the Medical Dictionary for Regulatory Activities version
19.0
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patients to have ASDAS-ID at consecutive
timepoints over at least 12 weeks, although the
overall induction period in C-OPTIMISE was
longer (48 vs. 28 weeks) [18]. Since there is no
widely established definition for clinical remis-
sion in axSpA, definitions used in previous,
mostly observational, studies have been
heterogeneous [19].
Using the study definition for sustained
remission, over 40% of patients had reached
sustained remission by week 48. All of these
patients were in sustained remission for at least
12 weeks, but 23.5% achieved and maintained
ASDAS-ID from week 4 onwards, and 52.0%
from week 24 onwards. This means that almost
a quarter of patients were in a state of deep
sustained remission for nearly a year (44 weeks),
and approximately half were in sustained
remission for 6 months.
The response to CZP was similar for r-axSpA
and nr-axSpA patients, with 42.8 and 45.3%,
respectively, achieving sustained remission.
Given that the burden of disease is similar
amongst the two axSpA subpopulations [6], the
finding that similar proportions of patients can
achieve clinical remission after CZP treatment
further supports the concept of axSpA as a sin-
gle disease, encompassing both r- and nr-axSpA.
Across other measures, responses showed
similar rapid and sustained improvements over
the 48-week treatment period. Over half of all
patients had reached ASAS PR, another measure
of remission, by the end of the induction per-
iod, with a fifth of patients achieving ASAS PR at
week 4. Improvements in patient mobility and
physical function were also observed, as asses-
sed by the BASMI and BASFI, respectively. As
the physical limitations of axSpA can impact on
many areas of a patient’s life, including
employment, social relationships and mood,
improvements in these outcomes are crucial to
patients’ quality of life [32, 33]. Indeed, there
were also improvements in the ASQoL and SF-
36 quality of life measures. Finally, patients also
demonstrated improvements in extra-muscu-
loskeletal and peripheral manifestations of dis-
ease, including enthesitis, uveitis, inflammatory
bowel disease and peripheral arthritis. For all
measures, responses were similar across r-axSpA
and nr-axSpA subpopulations, further
validating the unified axSpA concept, and sup-
porting results from a recent meta-analysis
which suggested that the treatment effect is
comparable in both subpopulations [6].
Structural progression of disease is a risk in
axSpA, both in r-axSpA and nr-axSpA, and has
an impact on the degree of disability experi-
enced by patients [34]. Active inflammation is
known to be a predictor of structural disease
progression, and is reflected in MRI outcomes
including ASspiMRI-a and SIJ SPARCC [35]. In
C-OPTIMISE, substantial improvements were
shown in ASspiMRI-a and SIJ SPARCC outcomes
in both subpopulations after 48 weeks of CZP
treatment.
The results from this study are also compa-
rable with previous studies assessing the efficacy
and tolerability of CZP in patients with axSpA
[14, 21]. RAPID-axSpA, a phase 3 randomized
controlled trial (NCT01087762), investigated
the effect of CZP on a broad axSpA population,
and was double-blind and placebo-controlled to
week 24, dose-blind to week 48 and open-label
to week 204 [14]. The study investigated
improvements in clinical and patient-reported
outcomes in a controlled setting, providing a
valuable comparison for the secondary out-
comes of this open-label trial across the same
time period [14]. After 48 weeks of treatment,
approximately 70 and 60% of patients in
RAPID-axSpA achieved ASAS20 and ASAS40,
respectively, compared to 79.6 and 72.0% in
this study [14]. It is possible that the increase in
the percentages of patients achieving ASAS20/
40 in C-OPTIMISE is attributable to the open-
label nature of this study period, as patients in
RAPID-axSpA were blinded up to week 48 [14].
However, the increase may also be affected by
the younger patient population in C-OPTIMISE
(mean patient age 32.9 years vs. 39.5 years in
RAPID-axSpA) or the shorter symptom duration
in C-OPTIMISE (median 3.5 years vs. 7.7 years
in RAPID-axSpA) [36].
Despite the overall lower ASAS40 response
rates in RAPID-axSpA, it is important to note
that similar percentages of patients with
r-axSpA and nr-axSpA achieved ASAS40 (ap-
proximately 59 and 57%, respectively), which
was also observed in C-OPTIMISE (71.3 and
72.9%, respectively) [14]. This indicates that
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r-axSpA and nr-axSpA patient populations
achieve similar ASAS40 outcomes, regardless of
open-label or blinded treatment, highlighting
that TNFi treatment is equally effective in both
patient groups.
Improvements in axSpA symptoms and
quality of life for patients during the induction
period of C-OPTIMISE were also comparable to
those observed in the C-axSpAnd trial
(NCT02552212), a double-blind, placebo-con-
trolled trial which focused on patients with nr-
axSpA [21]. In C-axSpAnd, 47.2% of patients
with nr-axSpA achieved ASDAS-MI (52-week
data), compared to 53.2% of patients with nr-
axSpA in C-OPTIMISE at 48 weeks [21].
Safety data reported for the induction period
of C-OPTIMISE were comparable to previous
reports for CZP in axSpA and no new safety
signals were identified [14, 21].
A potential limitation of the induction per-
iod of C-OPTIMISE is the fact that it was open-
label with no placebo comparator arm, which
may introduce an element of bias to the
observed improvements, particularly as many of
the outcomes are patient-reported. Indeed,
clinical responses during the induction period
such as ASAS20/40 were higher than in previous
double-blinded studies of CZP in axSpA, indi-
cating that perception bias may have impacted
the outcomes [14, 21]. However, it is also
important to note that there were large
improvements in objective measures such as
MRI outcomes.
In summary, the induction period of
C-OPTIMISE evaluated the achievement of sus-
tained remission in patients across the axSpA
spectrum in a controlled setting. Sustained
remission was achieved in over 40% of patients
during 48 weeks of open-label treatment with
CZP, demonstrating the benefits of early treat-
ment in patients with axSpA. Improvements in
disease activity and other outcome measures
were comparable across r-axSpA and nr-axSpA
patient groups, supporting the findings of pre-
vious studies in this area, with no new safety
signals identified.
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